University of California , Santa Barbara (UCSB)United States
Frank L. Brown is a Professor of Chemistry & Biochemistry at the University of California, Santa Barbara, with a joint appointment in Physics and the Biomolecular Sciences & Engineering (BMSE) program. His research focuses on theoretical and computational studies at the interface of physical chemistry and biophysics, particularly biomembrane dynamics and spectroscopy. Dr. Brown received his B.S. in Chemistry and B.A. in Applied Mathematics from UC Berkeley, followed by a Ph.D. in Physical Chemistry from MIT. He has held postdoctoral appointments at UC San Diego and the University of Chicago before joining UCSB in 2001. He is the recipient of prestigious awards including the Alfred P. Sloan Research Fellowship and the Presidential Early Career Award in Science and Engineering. His laboratory employs tools from statistical mechanics, hydrodynamics, and quantum mechanics to study biomembrane structure, dynamics, and interactions with embedded proteins. Key research areas include lipid bilayer fluctuations, membrane protein diffusion, and interpretation of spectroscopic techniques like single-molecule fluorescence and neutron spin echo. Dr. Brown has mentored numerous graduate students and postdoctoral researchers, with notable alumni including Brian Camley, Max Watson, and Golan Bel. His research is supported by grants from agencies such as the National Science Foundation and the Department of Energy. He directs the Brown Research Group, which collaborates with institutions like the CNSI Center for Scientific Computing. His work bridges computational modeling and experimental biophysics, advancing understanding of membrane systems in health and disease.
Massachusetts Institute of TechnologyUnited States
Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
University of California, Los AngelesUnited States
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
University of California, Los AngelesUnited States
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.
Andrew D. White is an Associate Professor of Chemical Engineering at the Hajim School of Engineering & Applied Sciences, University of Rochester. He holds a PhD from the University of Washington (2013). His research focuses on automating scientific discovery through AI, particularly leveraging large language models (LLMs) and deep learning techniques in chemistry. His lab develops agents that integrate literature analysis, hypothesis generation, and experimental design to advance fields like molecular dynamics and drug discovery. Education: PhD in Chemical Engineering, University of Washington, 2013 BS/MS (not explicitly stated in text, inferred from career timeline) Research Interests: Large language models for scientific automation Deep learning applications in chemistry and materials science Molecular dynamics simulations Scientific agents and autonomous systems Publications: His work includes groundbreaking studies on closed-loop AI systems for chemistry, federated learning in molecular property prediction, and multi-agent systems for drug discovery. Recent highlights include the Robin system and ChemCrow tools. Awards: Recipient of the NSF Career Award (2018), NIH Outstanding Investigator Award (2020), and the Curtis Teaching Award (2019). He also advises biotech companies and serves on the National Academy of Sciences' Chemical Sciences Roundtable. Grants & Funding: Supported by DOE, NSF (multiple grants including CBET-1751471), NIH (R35GM137966), and LLNL projects. Collaborates with institutions like Argonne National Lab and Qubit Pharmaceuticals. Labs & Teams: Leads the White Lab at Rochester and co-founded FutureHouse, a nonprofit advancing AI-driven scientific discovery. Supervises a multidisciplinary team of PhD students and postdocs in computational chemistry, AI, and biophysics.
University of California , Santa Barbara (UCSB)United States
Frank L. H. Brown is a Professor at the University of California, Santa Barbara with joint appointments in the Department of Physics and Department of Chemistry and Biochemistry. His research focuses on theoretical and computational approaches to understanding biomembrane dynamics and related biophysical phenomena, situated within the College of Letters and Science. Dr. Brown's research interests span the interface between physical chemistry and biophysics. He employs a variety of theoretical tools including statistical mechanics , hydrodynamics , elasticity theory , and quantum mechanics to study complex biological systems. His work particularly emphasizes the dynamics and structure of biomembranes and the interpretation of various spectroscopy experiments including single molecule fluorescence, neutron spin echo, and flicker spectroscopy. Analysis of his publication record reveals a consistent focus on computational modeling of lipid bilayers, membrane proteins, and related phenomena, with particular emphasis on developing novel theoretical frameworks for understanding membrane behavior across multiple scales. Dr. Brown leads an active research group that includes current members Ehsan Noruzifar (Postdoctoral Researcher) and Sean Cray (Graduate Student). His former group members include numerous successful scientists such as Grace Brannigan, Brian Camley, Lawrence Lin, and Max Watson who completed their graduate studies under his supervision, along with several postdoctoral researchers. His research has been supported by funding that enables theoretical and computational investigations of biomembrane systems. The Brown Research Group operates at the intersection of physics, chemistry, and biology, with facilities connected to the Biomolecular Sciences & Engineering Program and the California NanoSystems Institute (CNSI) at UCSB. Their work combines advanced computational techniques with theoretical physics to address fundamental questions about soft and living matter systems, particularly at biological interfaces.
Mayo Clinic College of Medicine and ScienceUnited States
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Jonathan Conway is an Assistant Professor in the Department of Chemical and Biological Engineering at Princeton University and an associated faculty member of the High Meadows Environmental Institute (HMEI). He leads the Conway Lab, which focuses on engineering plant-microbe interactions for applications in bioagriculture, bioenergy, and biochemical industries. Education: B.S. Chemical Engineering, University of Notre Dame (2011) M.S. Chemical Engineering, North Carolina State University (2013) Ph.D. Chemical Engineering, North Carolina State University (2017) Postdoctoral Fellow, University of North Carolina Chapel Hill & Howard Hughes Medical Institute (2017-2021) Research Interests: The Conway Lab develops genetic engineering approaches for non-model bacteria at plant-microbe interfaces. Key research areas include: chemical signaling between plants and microbes, microbiome impacts on plant immunity, environmental stress responses in agricultural systems, and enzymatic degradation of lignocellulosic biomass using thermophilic bacteria. The lab employs bacterial genetics, systems biology, and biomolecular engineering to create technologies for sustainable bioindustries. Publication Trends: Recent work demonstrates strong emphasis on molecular mechanisms of plant-microbe communication (2020-2024), enzyme characterization in biomass degradation (2024-2025), and development of synthetic microbial communities for climate resilience (2024). Earlier research focused on extremophile enzymology and metabolic engineering (2012-2019). Student Advising: Currently mentors 4 graduate students and 8 undergraduates. Alumni include 9 former advisees who graduated between 2022-2024. The lab actively recruits students through Princeton's Chemical Engineering graduate program and undergraduate research initiatives. Laboratory: The Conway Lab develops microfluidic systems for root microbiome studies and genetic tools for engineering plant-associated bacteria. Current projects include designing thermophilic microbial consortia for consolidated bioprocessing and characterizing bacterial immune evasion strategies.
Megan L. Matthews is an Assistant Professor in the Department of Chemistry at the University of Pennsylvania, School of Arts & Sciences, where she leads an active research group focused on chemical biology and enzymology. Her lab develops innovative chemical proteomics technologies to uncover novel enzyme cofactors and regulatory post-translational modifications, particularly those involving reactive electrophiles, which cannot be predicted from genomic sequences. B.S. in Chemistry, Miami University (2005) Ph.D. in Chemistry, The Pennsylvania State University (2011) Postdoctoral Fellow, The Scripps Research Institute (2012–2017) Her research centers on the concept of the 'electrophilome'—a largely unexplored half of the reactive proteome. By designing 'reverse-polarity' chemical probes, her group enables the discovery of functionally significant electrophilic modifications in proteins, especially those involved in cancer and Alzheimer’s disease. These discoveries open new avenues for therapeutic intervention through covalent targeting. The recent publications demonstrate a consistent focus on enzyme mechanisms, cofactor discovery, and chemical probe development. Her work spans from fundamental enzymology (e.g., halogenases, ribonucleotide reductases) to applied chemical biology (e.g., hydrazine probes, chemoproteomic profiling). The keywords across her publications highlight emerging themes in metalloenzymes, radical chemistry, and covalent proteome mapping. Her scientific contributions have been recognized through prestigious fellowships, including the Merck Helen Hay Whitney Postdoctoral Fellowship. She has published in top-tier journals such as Nature , Nature Chemical Biology , and Journal of the American Chemical Society . Dr. Matthews advises graduate students and postdoctoral researchers in her lab, fostering a collaborative and inclusive environment. Her lab emphasizes the importance of diverse perspectives in scientific discovery. She has secured research funding to support projects in probe development, target characterization, and disease mechanism studies, particularly in neurodegenerative diseases and cancer. The Matthews Lab is actively engaged in advancing reverse-polarity activity-based protein profiling (RP-ABPP) for in vivo applications and inhibitor screening. The group collaborates with experts in structural biology, spectroscopy, and disease modeling to translate basic discoveries into therapeutic insights.
University of North Carolina at Chapel HillUnited States
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Jerelle A. Joseph is an Assistant Professor at Princeton University , affiliated with the Department of Chemical and Biological Engineering and the Omenn-Darling Bioengineering Institute . They also hold associated faculty roles in the Department of Chemistry , Andlinger Center for Energy and the Environment , Princeton Institute for Computational Science and Engineering , and the Biophysics Graduate Program . Research Interests : The Joseph Group investigates the physicochemical principles governing biomolecular condensate formation, dissolution, and misregulation . Their work focuses on phase separation mechanisms , computational modeling of protein-RNA interactions , and engineering condensates for biomedical and sustainability applications , including therapeutic targeting of neurodegenerative diseases and design of synthetic microreactors . Scientific Awards : NIGMS MIRA (R35) Award (2024) Biophysical Society Award Lecture (2024) Chan Zuckerberg Initiative Investigator (2023) Postdoctoral Award, Biophysical Society IDP Subgroup (2022) Rising Star in Soft and Biological Matter (University of Chicago, 2020) Advising : Dr. Joseph advises graduate students including Ananya Chakravarti , Dominic Curtis , and Pablo Garcia . The group develops chemically-specific coarse-grained models using molecular dynamics , Monte Carlo sampling , and machine learning to study condensate microstructure , aging dynamics , and surface electrostatics .
Wei-Jen Tang is a Professor at the University of Chicago, affiliated with the Ben May Department of Cancer Research. His work integrates structural biology and biochemistry to study protein interactions critical to human health, particularly in Alzheimer's disease, diabetes, and bacterial pathogenesis. Education: B.S. in Zoology, National Taiwan University; Ph.D. in Biological Sciences, University of Texas, Austin; Postdoctoral training in Virology and Pharmacology at University of Texas Southwestern. His research focuses on: Amyloid Peptide-Degrading Proteases: IDE and PreP for Alzheimer's and diabetes. Chemokines: CCL5 and CCL3 in inflammation and HIV. Bacterial Toxins: Edema factor in anthrax and bio-defense. Recent publications highlight structural insights into IDE, PreP, and anthrax toxins, with keywords spanning Structural Biology , Biochemistry , and Therapeutics . Funding includes NIH and American Heart Association grants. Awards include AHA Established Investigator and Cancer Research Foundation Young Investigator. Lab updates note new members and a 2025 publication on PreP.
